Clinical trial
Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma…
NCT00052208 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00052208 |
|---|---|
| Title | Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme |
| Official title | A Phase I/II Study of an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), ZD 1839 (Iressa), [NSC #715055] With Radiation Therapy in Glioblastoma Multiforme |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Collaborators | NRG Oncology |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma |
| Intervention type | Drug, Other, Radiation |
| Interventions | gefitinib, radiation therapy, laboratory biomarker analysis |
| Enrollment | 158 |
| Start date | Mar 1, 2002 |
| Primary completion | Jun 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Oct 30, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: